Search

Your search keyword '"P.A. Fasching"' showing total 33 results
Start Over Author "P.A. Fasching"
33 results on '"P.A. Fasching"'

1. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients

Author

C.C. Hack, L. Häberle, S.Y. Brucker, W. Janni, B. Volz, C.R. Loehberg, A.D. Hartkopf, C.-B. Walter, G. Baake, A. Fridman, W. Malter, R. Wuerstlein, N. Harbeck, O. Hoffmann, S. Kuemmel, B. Martin, C. Thomssen, H. Graf, C. Wolf, M.P. Lux, C.M. Bayer, C. Rauh, K. Almstedt, P. Gass, F. Heindl, T. Brodkorb, L. Willer, C. Lindner, H.-C. Kolberg, P. Krabisch, M. Weigel, D. Steinfeld-Birg, A. Kohls, C. Brucker, V. Schulz, G. Fischer, V. Pelzer, B. Rack, M.W. Beckmann, T. Fehm, A. Rody, N. Maass, A. Hein, P.A. Fasching, and N. Nabieva

Subjects
Breast cancer, Endocrine therapy/treatment, Aromatase inhibitors, Letrozole, Integrative medicine, Complementary and alternative medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment — e.g., with letrozole. Letrozole often induces myalgia/limb pain and arthralgia, with potential noncompliance and treatment termination. This analysis investigated whether CAM before aromatase inhibitor (AI) therapy is associated with pain development and the intensity of AI-induced musculoskeletal syndrome (AIMSS) during the first year of treatment. Patients and methods: The multicenter phase IV PreFace study evaluated letrozole therapy in postmenopausal, hormone receptor–positive patients with early BC. Patients were asked about CAM use before, 6 months after, and 12 months after treatment started. They recorded pain every month for 1 year in a diary including questions about pain and numeric pain rating scales. Data were analyzed for patients who provided pain information for all time points. Results: Of 1396 patients included, 901 (64.5%) had used CAM before AI treatment. Throughout the observation period, patients with CAM before AI treatment had higher pain values, for both myalgia/limb pain and arthralgia, than non-users. Pain increased significantly in both groups over time, with the largest increase during the first 6 months. No significant difference of pain increase was noted regarding CAM use. Conclusions: CAM use does not prevent or improve the development of AIMSS. Pain intensity was generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment discontinuation due to the development of higher pain levels, special attention must be paid to patient education and aftercare in these patients.

Published
2020
Full Text
View/download PDF

2. TEMPORARY REMOVAL: Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

N. Harbeck, P.A. Fasching, R. Würstlein, T. Degenhardt, D. Lüftner, R.E. Kates, J. Schumacher, P. Räth, O. Hoffmann, R. Lorenz, T. Decker, M. Reinisch, T. Göhler, P. Staib, O. Gluz, T. Schinköthe, and M. Schmidt

Subjects
Oncology, Hematology
Published
2023

4. 195P Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

Author

N. Harbeck, R.E. Kates, T. Schinköthe, J. Schumacher, T. Degenhardt, R. Würstlein, D.I. Lüftner, O. Hoffmann, P. Raeth, R. Lorenz, T. Decker, M. Reinisch, T. Göhler, P. Staib, O. Gluz, P.A. Fasching, and M. Schmidt

Subjects
Cancer Research, Oncology
Published
2023

9. 144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study

Author

A. Bardia, T.M. Fernando, P.A. Fasching, V. Quiroga Garcia, Y.H. Park, J.M. Giltnane, C. Xue, V. Lopez Valverde, J. Steinseifer-Szabo, P.D. Pérez-Moreno, H.M. Moore, and S.A. Hurvitz

Subjects
Oncology, Hematology
Published
2022

11. 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial

Author

D. Lorusso, M-A. Mouret-Reynier, P. Harter, C. Cropet, C. Caballero Diaz, E. Petru, T. Satoh, I.B. Vergote, G. Parma, T. Jakobi Nøttrup, C. Lebreton, P.A. Fasching, C. Pisano, L. Manso, H. Bourgeois, I. Runnebaum, A-C. Hardy-Bessard, A. Schnelzer, E. Pujade-Lauraine, and I.L. Ray-Coquard

Subjects
Cancer Research, Oncology
Published
2023

12. Corrigendum to 'A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study'

Author

S. Loibl, M. Untch, N. Burchardi, J. Huober, B.V. Sinn, J.-U. Blohmer, E.-M. Grischke, J. Furlanetto, H. Tesch, C. Hanusch, K. Engels, M. Rezai, C. Jackisch, W.D. Schmitt, G. von Minckwitz, J. Thomalla, S. Kümmel, B. Rautenberg, P.A. Fasching, K. Weber, K. Rhiem, C. Denkert, and A. Schneeweiss

Subjects
Oncology, Hematology
Published
2022

15. 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa

Author

S. Loibl, M. Reinisch, C. Denkert, P.A. Fasching, S. Seiler, T. Link, C. Hanusch, V. Bjelic-Radisic, A. Schneeweiss, J. Huober, C. Jackisch, K.E. Rhiem, M. Untch, C. Solbach, J-U. Blohmer, T. Buechele, V. Nekljudova, and S. Loi

Subjects
Oncology, Hematology
Published
2022

16. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Author

F. Marmé, C. Hanusch, J. Furlanetto, P. Morris, T. Link, C. Denkert, P.A. Fasching, C. Jackisch, S. Antolín, C. Solbach, P. Aftimos, J. Huober, M. Untch, M. Balic, M. Reinisch, J-U. Blohmer, A. Gonçalves, J. Rey, T. Büchele, and S. Loibl

Subjects
Oncology, Hematology
Published
2022

19. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

Author

J. Furlanetto, F. Marmé, C. Thode, V. Nekljudova, Y. Liu, M. Martin Jimenez, T. Reimer, E. Knudsen, C. Denkert, M. Bassy, L-A. Martin, T. Karn, B.V. Sinn, M. Filipitis, M. van Mackelenbergh, P.A. Fasching, V. Müller, E. Stickeler, C. Schem, and S. Loibl

Subjects
Oncology, Hematology
Published
2022

23. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

Author

M. Reinisch, J-U. Blohmer, T. Link, M. Just, M. Untch, O. Stötzer, P.A. Fasching, A. Schneeweiss, P. Wimberger, S. Seiler, J. Huober, M. Thill, C. Jackisch, K. Rhiem, C. Solbach, C. Hanusch, C. Denkert, K. Engels, V. Nekljudova, and S. Loibl

Subjects
Oncology, Hematology
Published
2022

24. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Author

N. Harbeck, P. Rastogi, M. Martin, S.M. Tolaney, Z.M. Shao, P.A. Fasching, C.S. Huang, G.G. Jaliffe, A. Tryakin, M.P. Goetz, H.S. Rugo, E. Senkus, L. Testa, M. Andersson, K. Tamura, L. Del Mastro, G.G. Steger, H. Kreipe, R. Hegg, J. Sohn, V. Guarneri, J. Cortés, E. Hamilton, V. André, R. Wei, S. Barriga, S. Sherwood, T. Forrester, M. Munoz, A. Shahir, B. San Antonio, S.C. Nabinger, M. Toi, S.R.D. Johnston, J. O’Shaughnessy, M.M. Jimenez, S. Johnston, F. Boyle, P. Neven, Z. Jiang, M. Campone, J. Huober, C. Shimizu, I. Cicin, A. Wardley, G.G. Abuin, J. Zarba, E. Lim, P. Sant, N. Liao, B. Christiansen, N. Eigeliene, J. Martin-Babau, J. Ettl, D. Mavroudis, J. Chiu, K. Boer, R. Nagarkar, S. Paluch-Shimon, L. Moscetti, Y. Sagara, S.-B. Kim, M.M. Maciel, V. Tjan-Heijnen, R. Broom, A. Lacko, M. Schenker, N. Volkov, Y. Sim Yap, M. Coccia-Portugal, J. Ángel García Sáenz, A. Andersson, T.-Y. Chao, E. Gokmen, H. Harputluoglu, O. Berzoy, D. Patt, H. McArthur, H. Chew, P. Chalasani, P. Kaufman, K. Tedesco, S.L. Graff, Institut Català de la Salut, [Harbeck N] Breast Center, Department of OB & GYN and CCC Munich, LMU University Hospital, Munich, Germany. [Rastogi P] University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA. [Martin M] Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain. [Tolaney SM] Dana-Farber Cancer Institute, Boston, USA. [Shao ZM] Fudan University Shanghai Cancer Center, Shanghai, China. [Fasching PA] University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. [Cortés J] International Breast Cancer Center (IBCC), Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Receptor, ErbB-2, abemaciclib, adjuvant, CDK4/6, early breast cancer, Ki-67, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Ki-67 Antigen, Neoplasm Recurrence, Local, Breast Neoplasms, medicine.medical_treatment, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], chemistry.chemical_compound, Tratamiento médico, ErbB-2, Clinical endpoint, Other subheadings::/therapeutic use [Other subheadings], Abemaciclib, education.field_of_study, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], biology, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Hematology, Cáncer, medicine.anatomical_structure, Local, Cohort, Neoplasias de la mama, Adjuvant, Receptor, medicine.medical_specialty, Axillary lymph nodes, Mujer, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Quimioteràpia combinada, Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine, Chemotherapy, education, business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], Interim analysis, Neoplasm Recurrence, chemistry, Mama - Càncer - Tractament, biology.protein, business
Abstract

Abemaciclib; Adjuvant; Early breast cancer Abemaciclib; Adjuvant; Càncer de mama precoç Abemaciclib; Adyuvante; Cáncer de mama precoz Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis. Patients and methods This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for ≥5 years ± abemaciclib for 2 years. Cohort 1 enrolled patients with ≥4 positive axillary lymph nodes (ALNs), or 1-3 positive ALNs and either grade 3 disease or tumor ≥5 cm. Cohort 2 enrolled patients with 1-3 positive ALNs and centrally determined high Ki-67 index (≥20%). The primary endpoint was IDFS in the intent-to-treat population (cohorts 1 and 2). Secondary endpoints were IDFS in patients with high Ki-67, DRFS, overall survival, and safety. Results At the primary outcome analysis, with 19 months median follow-up time, abemaciclib + ET resulted in a 29% reduction in the risk of developing an IDFS event [hazard ratio (HR) = 0.71, 95% confidence interval (CI) 0.58-0.87; nominal P = 0.0009]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (HR = 0.70, 95% CI 0.59-0.82; nominal P < 0.0001) and DRFS (HR = 0.69, 95% CI 0.57-0.83; nominal P < 0.0001) benefit was maintained. The absolute improvements in 3-year IDFS and DRFS rates were 5.4% and 4.2%, respectively. Whereas Ki-67 index was prognostic, abemaciclib benefit was consistent regardless of Ki-67 index. Safety data were consistent with the known abemaciclib risk profile. Conclusion Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67 index. Overall, the robust treatment benefit of abemaciclib extended beyond the 2-year treatment period. This work was supported by the sponsor (Eli Lilly and Company) and designed together with the study Executive Committee (no grant number).

Published
2021

25. LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

Author

P. Neven, P.A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G.V. Bianchi, M. Martin Jimenez, A. Nusch, G.S. Sonke, L. de la Cruz Merino, J.T. Beck, J.P. Zarate, Y. Wang, A. Chakravartty, C. Wang, and D. Slamon

Subjects
Oncology, Hematology
Published
2022

26. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’

Author

D.J. Slamon, P. Neven, S. Chia, G. Jerusalem, M. De Laurentiis, S. Im, K. Petrakova, G. Valeria Bianchi, M. Martín, A. Nusch, G.S. Sonke, L. De la Cruz-Merino, J.T. Beck, Y. Ji, C. Wang, U. Deore, A. Chakravartty, J.P. Zarate, T. Taran, and P.A. Fasching

Subjects
Oncology, Hematology
Published
2021

27. 2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial

Author

A. Llop-Guevara, V. Vladimirova, A. Schneeweiss, G. Villacampa, T. Karn, D-M. Zahm, A. Herencia-Ropero, P. Jank, M. van Mackelenbergh, P.A. Fasching, F. Marmé, E. Stickeler, C. Schem, R. Dienstmann, S. Florian, V. Nekljudova, J. Balmaña, C. Denkert, S. Loibl, and V. Serra

Subjects
Oncology, Hematology
Published
2021

28. Sebaziöses Mammakarzinom

Author

P.A. Fasching, C. Rauh, D.L. Wachter, M.W. Beckmann, E. Wenkel, and A. Hartmann

Subjects
Pathology and Forensic Medicine
Abstract

Wir berichten uber den Fall eines sebaziosen Karzinoms als sehr seltenen histologischen speziellen Subtyp des Mammakarzinoms. Aufgrund der Raritat derartiger Tumoren werden insbesondere differenzialdiagnostische Uberlegungen beleuchtet sowie der Ausschluss einer Assoziation mit dem Muir-Torre-Syndrom beschrieben. Zuletzt folgt eine kurze Diskussion mit Uberlegungen hinsichtlich der moglichen Entstehung des Tumors sowie bzgl. der Therapie.

Published
2014

29. Körperliche Bewegung und Sport zur Prävention und Behandlung von Krebskrankheiten

Author

P.A. Fasching, J. Hübner, and U.R. Kleeberg

Subjects
Gynecology, medicine.medical_specialty, Oncology, business.industry, Medicine, Hematology, business
Abstract

Weltweit machen Lebensumstande ca. 50–75% des Krebsrisikos aus. Bei einer wachsenden Zahl von Malignomen ist Bewegungsmangel neben Adipositas und Fehlernahrung von kritischer Bedeutung. Insulinartige Wachstumsfaktoren (IGF) stellen das Bindeglied zwischen Adipositas, Bewegungsmangel und Krebs dar. Gegebenenfalls sind sie mitverantwortlich fur die Entwicklung einer endokrinen Therapieresistenz. Die Beeinflussung des Glukose- und Insulinstoffwechsels entwickelt sich als neue und erganzende Strategie gegen malignes Zellwachstum. Das Zusammenwirken von korperlicher Aktivitat und Ernahrungsweise wird fur den klinischen Einsatz im Sinne von EBM mit dem Evidenzgrad IA bewertet. Der gunstige Effekt einer solchen Lebensfuhrung, ist, wie prospektive, randomisierte Phase-III-Studien zeigen, dem einer adjuvanten endokrinen oder zytostatischen Therapie moglicherweise gleichwertig. Dem Wunsch des Patienten, selbst zum Therapieerfolg beizutragen, kann fundiert entsprochen werden, und es besteht die Chance, ihn so mit einer nachhaltigen Anleitung zu taglicher korperlicher Aktivitat und einem optimalen Korpermassenindex (Body-Mass-Index, BMI) vor einem irrealen Einsatz ungeprufter sog. komplementarer und alternativer Medizin (KAM) zu bewahren.

Published
2009

30. Contents Vol. 73, 2007

Author

C.E. Nwogu, A.N. Tenekeci, Pierre Michel, Michihide Mitsumori, Kohkichi Hata, Mariana Capurro, S. Maddipatla, R.V. Iyer, Eiji Miyoshi, H.J. Stemmler, Rosangela Romano, A. Douglas-Jones, B. Kalischefski, Sylvie Negrier, D. Laessig, J. Robson, Domenico Germano, Wong Benjamin Chun Yu, Torello Lotti, Chen Minhu, Peixing Wu, Jie Zhang, G. Paganelli, Metin Karakok, Rafael Roesler, P.A. Fasching, Toshinao Onoda, Takatsugu Kan, Tsuneo Tanaka, Hideyuki Ohnuma, Yasuhito Tonomoto, M. Stauch, Sung Ho Choi, Hui Yan Li, R.E. Mansel, C. Poettgen, S. Raj, Yan Wang, Daniela Massi, Xiaoyan Yang, Thomas Krbek, B. Sakar, Bülent Akgul, H. Kynaston, Dipok Kumar Dhar, H. Kölbl, Satoshi Shiojima, Vincenzo De Giorgi, J.D. Black, Bin Zhou, Evangelos Karayiotis, Seungmin Bang, Hong-zhi Luo, Akira Myoumoto, Bing Xu, Hitoshi Nobumasa, Pu Wang, Serena Sestini, Go Watanabe, Yutaka Shimada, Ibrahim Sari, S.R. Davies, Tadashi Kadowaki, Si Young Song, Shinichi Miyamoto, Meletios A. Dimopoulos, Bai Aiping, G. Loewen, P. Maubach, Akira Miyauchi, Shen Benchang, F. Melchert, Shigemi Matsumoto, G. Morack, J. Alkhaddo, N. Natarajan, Atsushi Itami, Zong-guang Zhou, Luise Meurer, Lie Yang, Hai-yi Liu, Naofumi Nagasue, Kanako Yamanaka, Dirk Theegarten, Giulia Lo Russo, Gazi Comez, Aristotle Bamias, M.E. Reid, David Tougeron, Efstathios Kastritis, Eiji Tanaka, A. Chhabra, Sabine Levegruen, Marios Froudarakis, Andreas Koureas, Celalettin Camci, Yavuz Pehlivan, Jeong Youp Park, F. Eid, Dirk Jaeger, Gozoh Tsujimoto, N. Ramnath, A.U. Pande, G. Watkins, H.S. Fernando, H. Meerpohl, Mehmet Emin Kalender, Katsuhisa Noda, Helmut Teschler, Gilberto Schwartsmann, Xiao-Feng Sun, Genny Leporatti, M.A. Ustaoglu, Tetsuo Ito, Martin Stuschke, V. Heinemann, Alper Sevinc, Toshinori Sato, Noriko Okuyama, Bernard Paillot, Olivier Rigal, Yuan Li, Andreas Bockisch, M. Basaran, Nikos Antoniou, P. Dua, Sadako Yamagata, D. Mazhar, Hiroshi Yoshida, Wolfgang Stremmel, S. Saglam, Mei Hou, Wilfried Eberhardt, R.J. Menezes, N.F. Aykan, Michael Chrisofos, Hitoshi Matsumoto, C.M. Levea, Anastassios V. Koutsopoulos, Georgios Stamatis, Hideo Akiyama, Li Xiaoyan, Ling Wang, H. Hamidou, Maurie Markman, Luigi Manzione, Andreas Skolarikos, Yu-jian Zeng, Mario Dini, Jorge Filmus, A.K. Dixon, Frédéric Di Fiore, Daniela Baumann Cornelio, M. Emin Kalender, Stephen J. Meltzer, Wang Jinhui, A. Argon, Tatsuya Yamagata, M. Gumus, Motoshige Higashiyama, B. Weber, Song Xin, G. Alivizatos, Jiang Zhu, Sung Hoon Noh, Thomas Gauler, Yasuhiro Ito, Thomas R. W. Herrmann, Christina Herrmann, Jinghai Zhang, Yong Soo Kim, U. Vehling-Kaiser, H. Mehmet Turk, Z. Ustuner, Hilmar Kuehl, Christelle De La Fouchardiere, Chen Huixin, Woo Jin Hyung, Georgia Karpathiou, M.M. Javle, Olivia Diaz, Evangelia Argiana, A. Scharl, Ulrich Abel, George Lainakis, Fumiaki Sato, W.G. Jiang, M.V. Williams, Romain Coriat, G.Y. Yang, N. Guney, Shiori Tomoda, A. Rani, Françoise Desseigne, Jun-min Song, and Mitsuo Tachibana

Subjects
Cancer Research, Oncology, General Medicine
Published
2007

31. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

Author

G. von Minckwitz, S. Loibl, M. Untch, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, J. Huober, C. Solbach, C. Jackisch, G. Kunz, J.U. Blohmer, M. Hauschild, T. Fehm, V. Nekljudova, B. Gerber, K. Gnauert, B. Heinrich, T. Prätz, U. Groh, H. Tanzer, C. Villena, A. Tulusan, B. Liedtke, J.-U. Blohmer, C. Mau, J. Potenberg, J. Schilling, M. Just, E. Weiss, U. Bückner, M. Wolfgarten, R. Lorenz, G. Doering, S. Feidicker, P. Krabisch, U. Deichert, D. Augustin, K. Kast, C. Nestle-Krämling, C. Höß, J. Terhaag, P. Fasching, P. Staib, B. Aktas, T. Kühn, F. Khandan, V. Möbus, E. Stickeler, G. Heinrich, H. Wagner, A. Abdallah, T. Dewitz, G. Emons, A. Belau, V. Rethwisch, T. Lantzsch, C. Thomssen, U. Mattner, A. Nugent, V. Müller, T. Noesselt, F. Holms, T. Müller, J.-U. Deuker, D. Strumberg, C. Uleer, E. Solomayer, I. Runnebaum, H. Link, O. Tomé, H.-U. Ulmer, B. Conrad, G. Feisel-Schwickardi, C. Schumacher, T. Steinmetz, I. Bauerfeind, S. Kremers, D. Langanke, U. Kullmer, A. Ober, D. Fischer, A. Kohls, W. Weikel, J. Bischoff, K. Freese, M. Schmidt, W. Wiest, M. Sütterlin, M. Dietrich, M. Grießhammer, D.-M. Burgmann, B. Rack, C. Salat, D. Sattler, J. Tio, E. von Abel, B. Christensen, U. Burkamp, C.-H. Köhne, W. Meinerz, S.-T. Graßhoff, T. Decker, F. Overkamp, I. Thalmann, A. Sallmann, T. Beck, T. Reimer, G. Bartzke, M. Deryal, M. Weigel, P. Weder, C.-C. Steffens, S. Lemster, A. Stefek, F. Ruhland, M. Hofmann, J. Schuster, W. Simon, U. Kronawitter, M. Clemens, W. Janni, K. Latos, W. Bauer, A. Roßmann, L. Bauer, D. Lampe, V. Heyl, G. Hoffmann, F. Lorenz-Salehi, J. Hackmann, and R. Schlag

Subjects
Adult, Oncology, medicine.medical_specialty, Bevacizumab, Receptor, ErbB-2, medicine.medical_treatment, Medizin, Angiogenesis Inhibitors, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Breast cancer, Internal medicine, medicine, Humans, Everolimus, Neoadjuvant therapy, Sirolimus, Chemotherapy, business.industry, Hematology, Middle Aged, medicine.disease, Survival Analysis, Chemotherapy regimen, Docetaxel, Chemotherapy, Adjuvant, Drug Therapy, Combination, Female, business, medicine.drug, Epirubicin
Abstract

Background The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane–based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. Patients and methods Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. Results With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1–3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. Conclusions Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline–taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. Clinical trial number NCT 00567554, www.clinicaltrials.gov .

Published
2014

32. Cancer detection in gynecology

Author

D. Jap, B. Kuschel, P.A. Fasching, S. P. Renner, M. W. Beckmann, and Y. Werner

Subjects
Gynecology, medicine.medical_specialty, business.industry, Obstetrics and Gynecology, Medicine, business
Abstract

Die Durchfuhrung der Krebsfruherkennung orientiert sich an den 1971 festgelegten Richtlinien des gesetzlichen Krebsfruherkennungsprogramms (GKFP). Untersuchte Organe sind das ausere und innere Genitale, die Mammae, die Haut sowie das Rektum und das Kolon. Die Methoden umfassen die gezielte Anamnese, die korperliche Untersuchung, die Anleitung zur Selbstuntersuchung der Mammae, den zytologischen Zervixabstrich und die Testung auf Blut im Stuhl. Die Durchfuhrung der Mammographie ist beschrankt auf Indikationen wie Zugehorigkeit zu anamnestischen Risikogruppen und manifesten Brustveranderungen. Im Jahr 2000 hat sich das Wissen im Bereich der Onkologie gewandelt. Die Ausrichtung und die Anspruche an das GKFP verandern sich durch diesen neuen Wissensstand. Gleichzeitig muss dies auch unter dem Gesichtspunkt reduzierter finanzieller Ressourcen im Gesundheitssystem mit Fokussierung auf eine maximale Effektivitat der eingesetzten Methoden, der erfassten Risikogruppen und auch der grosten Compliance der Frauen aus diesen Gruppen erfolgen. Ein Screening aller Bevolkerungsgruppen erscheint unter diesen Aspekten nicht durchfuhrbar. Durch die Integration von Risikoberechnungen, Information und Aufklarung uber Pravention und Prophylaxe und Motivation zur Teilnahme konnte das Fruherkennungsprogramm in ein umfassenderes, individualisiertes Vorsorgeprogramm gewandelt werden.

Published
2000

33. Subject Index Vol. 73, 2007

Author

Serena Sestini, W.G. Jiang, Hideo Akiyama, Maurie Markman, M. Emin Kalender, Kohkichi Hata, Rosangela Romano, M. Basaran, Martin Stuschke, Satoshi Shiojima, Anastassios V. Koutsopoulos, Ibrahim Sari, Zong-guang Zhou, Georgia Karpathiou, M.M. Javle, Christelle De La Fouchardiere, Nikos Antoniou, Jie Zhang, Olivier Rigal, Yavuz Pehlivan, Atsushi Itami, Naofumi Nagasue, Wang Jinhui, N.F. Aykan, Michael Chrisofos, Hitoshi Matsumoto, Wilfried Eberhardt, H. Hamidou, Giulia Lo Russo, R.J. Menezes, Chen Huixin, A. Douglas-Jones, A. Scharl, Helmut Teschler, Romain Coriat, G.Y. Yang, Toshinao Onoda, N. Guney, G. Morack, Gozoh Tsujimoto, Torello Lotti, J. Robson, Li Xiaoyan, J. Alkhaddo, Go Watanabe, Yu-jian Zeng, A.K. Dixon, G. Watkins, Yutaka Shimada, Motoshige Higashiyama, S. Maddipatla, Shiori Tomoda, Ulrich Abel, Eiji Tanaka, Sabine Levegruen, Frédéric Di Fiore, Thomas Krbek, Andreas Skolarikos, Domenico Germano, George Lainakis, Gilberto Schwartsmann, Xiao-Feng Sun, Mehmet Emin Kalender, Tadashi Kadowaki, Si Young Song, A. Argon, Hideyuki Ohnuma, Tatsuya Yamagata, Yasuhito Tonomoto, Alper Sevinc, M. Stauch, Ling Wang, Jiang Zhu, Yuan Li, S.R. Davies, Bai Aiping, Sung Ho Choi, Daniela Baumann Cornelio, Genny Leporatti, A. Rani, U. Vehling-Kaiser, Takatsugu Kan, Yasuhiro Ito, C. Poettgen, Dirk Theegarten, Song Xin, B. Kalischefski, Christina Herrmann, Sylvie Negrier, Mei Hou, Pierre Michel, Bülent Akgul, D. Laessig, Dipok Kumar Dhar, Fumiaki Sato, C.M. Levea, Wolfgang Stremmel, F. Eid, Dirk Jaeger, A.U. Pande, Bin Zhou, Meletios A. Dimopoulos, Woo Jin Hyung, Aristotle Bamias, David Tougeron, D. Mazhar, Hiroshi Yoshida, Bernard Paillot, Luise Meurer, Wong Benjamin Chun Yu, Gazi Comez, H.J. Stemmler, S. Saglam, A. Chhabra, Olivia Diaz, Jeong Youp Park, Evangelia Argiana, Akira Myoumoto, Bing Xu, Thomas Gauler, Hitoshi Nobumasa, Xiaoyan Yang, Tetsuo Ito, M.V. Williams, S. Raj, Toshinori Sato, Luigi Manzione, Mario Dini, H. Mehmet Turk, Jorge Filmus, Chen Minhu, Peixing Wu, Michihide Mitsumori, Z. Ustuner, Katsuhisa Noda, Françoise Desseigne, Jun-min Song, Mariana Capurro, Shen Benchang, Andreas Bockisch, Stephen J. Meltzer, G. Loewen, M.E. Reid, N. Natarajan, R.V. Iyer, Mitsuo Tachibana, Seungmin Bang, Lie Yang, Kanako Yamanaka, H. Kölbl, P. Maubach, Akira Miyauchi, C.E. Nwogu, M.A. Ustaoglu, A.N. Tenekeci, M. Gumus, V. Heinemann, Eiji Miyoshi, B. Weber, Noriko Okuyama, B. Sakar, Shinichi Miyamoto, N. Ramnath, Yan Wang, Shigemi Matsumoto, Rafael Roesler, Sung Hoon Noh, Hui Yan Li, Pu Wang, H. Meerpohl, Daniela Massi, J.D. Black, Georgios Stamatis, Marios Froudarakis, Andreas Koureas, Celalettin Camci, G. Alivizatos, P. Dua, Sadako Yamagata, Thomas R. W. Herrmann, Jinghai Zhang, Vincenzo De Giorgi, Yong Soo Kim, Hilmar Kuehl, Efstathios Kastritis, Evangelos Karayiotis, F. Melchert, Hai-yi Liu, G. Paganelli, R.E. Mansel, Metin Karakok, P.A. Fasching, H. Kynaston, Hong-zhi Luo, H.S. Fernando, and Tsuneo Tanaka

Subjects
Cancer Research, Index (economics), Oncology, Statistics, Subject (documents), General Medicine, Mathematics
Published
2007

Catalog

Books, media, physical & digital resources
See catalog results